Jonathan W. Friedberg
Director - Cancer Center
Credentials: · · ·
History
Present- Present
- 1997–1999
- 1995–1997
- 1994–1995
Research
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
New England Journal of Medicine · 2017 · 4,914 citations
Blood · 2022 · 1,363 citations
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
New England Journal of Medicine · 2022 · 793 citations
- BK
64 papers
50 papers
- RF
48 papers
44 papers · 1 as a fellow
43 papers
40 papers
40 papers
40 papers
Grants
- 2025–2030
University of Rochester Wilmot Cancer Institute Support Grant
National Cancer Institute · P30
Contact PI · $4.3M · University of Rochester
- 2017–2024
Vitamin D and Follicular Lymphoma
National Cancer Institute · R01
Contact PI · $3.3M · University of Rochester
- 1978–2015
- 2008–2014
Clinical trials
- 2019–2022
Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors
Principal investigator · Completed · Early phase 1
University of Rochester
- 2017–2024
A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma
Principal investigator · Completed · Phase 3
Jonathan Friedberg
- 2011–2015
Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma
Principal investigator · Completed · Phase 1
University of Rochester
- 2010–2012
A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
Principal investigator · Completed · Phase 2
S*BIO